Intricon CORP: directors' dealings · United States · SEC (Form 4)

About Intricon CORP

IntriCon Corp. (ticker IIN) is a U.S.-listed company traded on the NASDAQ in the United States, focused on the design and manufacture of micromedical devices and miniature assemblies. The company traces its roots back to 1930, when it was originally formed in Pennsylvania, while its modern business was built around body-worn technologies and connected-health applications. Its headquarters are in Arden Hills, Minnesota, and it operates with an international footprint across North America, Europe, and Asia. For French-speaking investors, IntriCon belongs to the healthcare industrial niche: a B2B technology supplier rather than a consumer-facing medical brand. IntriCon’s core business is to support medical device manufacturers and professional communications customers through co-development, industrialization, and production of very small, high-precision components and devices. The company designs, engineers, manufactures, and distributes micro-miniature products, microelectronic and micro-mechanical subassemblies, and complete device solutions serving growth markets such as hearing healthcare, medical bio-telemetry, and professional audio communications. This makes IntriCon more of a technology partner than a pure contract manufacturer, with value creation centered on miniaturization, systems integration, and precision manufacturing. From a competitive standpoint, IntriCon operates in markets where technical know-how, product qualification, long customer relationships, and manufacturing discipline matter more than scale alone. Its business model benefits from co-engineering capabilities, complex manufacturing processes, and the ability to serve OEM customers that require reliability, repeatability, and shorter time-to-market. Key products and services include micro-mechanical components, electronic assemblies, body-worn devices, and integrated manufacturing solutions for medical and communications partners. Geographically, the company’s multi-site footprint is strategically important. It operates through facilities in the United States and abroad, giving it the ability to support a global customer base and diversify parts of its production chain. A notable recent development was the expansion of its Arden Hills headquarters announced in January 2025, aimed at increasing production capacity, which suggests continued demand and operational investment. Overall, IntriCon remains a specialized healthcare industrial company: relatively small in size, but exposed to structurally attractive end markets, with a niche position that may interest investors looking for medical-device supply-chain exposure on the NASDAQ in the United States.